Benzinga · Aug 10, 2026
Benchmark Downgrades BioLife Solutions to Hold
Benchmark analyst Robert Wasserman downgrades BioLife Solutions (NASDAQ:BLFS) from Buy to Hold.
NASDAQ · BLFS
BioLife Solutions, Inc.
Healthcare · Medical - Instruments & Supplies
$37.10
Up+$0.13 (+0.35%)
Updated Aug 22, 2026, 1:41 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.2B
- P/E ratio
- -215.22
- Dividend yield
- 0.00%
- 52-week range
- $17.86 – $38.10
- Volume
- 750.37K
- Avg. volume
- 367.9K
Price performance
BLFS price history
1M range · 21 trading sessions · Daily adjusted prices
BLFS closed at $37.10 after 21 trading sessions, up 23.75% for the selected period.
- Last close
- $37.10
- Period change
- +23.75%
- Period low
- $29.79
- Period high
- $37.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $36.89 | $37.28 | $36.29 | $37.10 | 750.37K |
| Aug 20, 2026 | $35.77 | $38.10 | $35.77 | $36.97 | 681.73K |
| Aug 19, 2026 | $35.45 | $36.91 | $35.45 | $36.47 | 703.14K |
| Aug 18, 2026 | $35.40 | $35.40 | $34.755 | $34.94 | 390.29K |
| Aug 17, 2026 | $34.77 | $35.46 | $34.7501 | $35.45 | 395.62K |
| Aug 14, 2026 | $35.17 | $35.22 | $34.81 | $35.07 | 478.68K |
| Aug 13, 2026 | $35.00 | $35.34 | $34.415 | $35.23 | 592.53K |
| Aug 12, 2026 | $35.12 | $35.14 | $34.52 | $34.97 | 348.53K |
| Aug 11, 2026 | $34.45 | $35.35 | $34.20 | $34.82 | 410.59K |
| Aug 10, 2026 | $33.79 | $34.925 | $33.751 | $34.64 | 447.92K |
| Aug 7, 2026 | $34.27 | $34.7614 | $34.12 | $34.66 | 655.86K |
| Aug 6, 2026 | $33.61 | $34.34 | $33.605 | $33.93 | 461.49K |
| Aug 5, 2026 | $32.57 | $33.84 | $32.57 | $33.80 | 600.92K |
| Aug 4, 2026 | $32.03 | $32.55 | $31.46 | $32.52 | 597.99K |
| Aug 3, 2026 | $31.35 | $32.19 | $31.28 | $32.15 | 575.98K |
| Jul 31, 2026 | $31.59 | $31.70 | $31.02 | $31.28 | 764.55K |
| Jul 30, 2026 | $31.50 | $31.82 | $31.21 | $31.64 | 436.92K |
| Jul 29, 2026 | $31.63 | $32.62 | $31.26 | $31.50 | 1.06M |
| Jul 28, 2026 | $30.05 | $33.14 | $30.05 | $31.98 | 2.71M |
| Jul 27, 2026 | $29.87 | $30.17 | $29.63 | $29.79 | 1.06M |
| Jul 24, 2026 | $30.36 | $30.725 | $29.92 | $29.98 | 2.61M |
Latest BLFS news
The latest Smart Investors Daily articles mentioning BLFS.
Stock researchCompany · Overview
BLFS research
Overview
Company profile and research snapshot.
Company profile
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $32.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Benchmark | Hold | — |
| Jul 27, 2026 | Stephens & Co. | Equal-Weight | — |
| Jul 23, 2026 | Jefferies | Hold | — |
| Jul 23, 2026 | TD Cowen | Hold | — |
| Jul 22, 2026 | Lake Street | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 2, 2026
Repligen: Acquisition To Add Cell Therapy Capabilities
Repligenâs $1.5B BioLife acquisition and strong Q2 results lift guidance, but valuation looks stretched. Click for more on RGEN stock.
Benzinga · Jul 27, 2026
Stephens & Co. Downgrades BioLife Solutions to Equal-Weight, Lowers Price Target to $31
Stephens & Co. analyst Helfey Hannah downgrades BioLife Solutions (NASDAQ:BLFS) from Overweight to Equal-Weight and lowers the price target from $32 to $31.
Benzinga · Jul 23, 2026
Jefferies Downgrades BioLife Solutions to Hold, Raises Price Target to $31
Jefferies analyst Matthew Stanton downgrades BioLife Solutions (NASDAQ:BLFS) from Buy to Hold and raises the price target from $30 to $31.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
